Duchenne News Tags: Sarepta Therapeutics

June 20, 2024
Breaking news: US FDA has expanded approval of Sarepta Therapeutics’ gene therapy, Elevidys to Duchenne muscular dystrophy patients ages 4 and above. Elevidys has received traditional FDA approval for ambulatory...
February 16, 2024
Sarepta announces the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application for ELEVIDYS.
October 31, 2023
Sarepta shares topline results from the EMBARK study and more in a Community Letter.
June 22, 2023
Sarepta announces U.S. Food and Drug Administration accelerated approval of ELEVIDYS.
June 8, 2023
Sarepta shares enrollment updates for SRP-9001-303 study.
May 24, 2023
Sarepta shares an update on the regulatory review of SRP-9001, a treatment of ambulant individuals with Duchenne muscular dystrophy who have a confirmed mutation of the DMD gene.
April 11, 2023
Sarepta Therapeutics Announces May 12, 2023 as Date of Advisory Committee Meeting for SRP-9001
March 17, 2023
Sarepta announces advisory meeting for SRP-9001, an investigational gene therapy for the treatment of Duchenne muscular dystrophy.
February 28, 2023
Sarepta announces official release of 2023-2024 Route 79 Duchenne Scholarship Program
November 28, 2022
Sarepta announces FDA filing and priority review for biologics license application for SRP-9001
September 29, 2022
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open